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ABSTRACT: The synthesis, the enantiomeric separation and the characterization of new simple 
spiroketal derivatives has been performed. The synthesised compounds have shown a very high 
anticancer activity. Cell proliferation assay showed that they induce a remarkable inhibition of cell 
proliferation in all cell lines treated, depending on culture time and concentration. The compounds 
have also shown a potent nanomolar human Telomerase inhibition activity and apoptosis 
induction. CD melting experiments demonstrate that spiroketal does not affect the G-quadruplex 
(G4) thermal stability. Docking studies showed that telomerase inhibition could be determined by 




 Numerous complex natural products containing spiroketals framework have been isolated 
over the years from marine or terrestrial sources and have shown a wide range of important 
biological activities.1,2 Among them, the spongistatins 1 are a family of marine macrolides that 
display remarkable antitumor activity,3 integramycin 2 is an HIV-1 intregrase inhibitor,4 
reveromycins 3 are polyketide type antibiotics inhibitors of mitogenic epidermal growth factor 
(EGF) activity,5-7 tautomycin 4 and okadaic acid 5 are protein phosphatase inhibitors,8-10 
spirofungin A 6 selectively inhibits the activity of isoleucyl-tRNA synthetase and displays 
antiproliferative activity of cancer cells,11 and the rubromycins that exhibit an array of 




Figure 1. Biologically active naturally occurring spiroketals 
 
Many groups started to investigate the possibility to reduce the complexity of spiroketal natural 
products while preserving their biological activity by focusing on the role of the spiroketal core on 
the biological activity of their natural models.17-19 
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So, the essential role of rubromycins spiroketal subunit for telomerase inhibition was 
demonstrated,12 and natural inspired spiroketals 8, 9 and 10 were synthesized showing interesting 
biological activity often retained from their parent natural products, while more recently, the 
simple spiroketal metabolite dinemasone A 11 was isolated from the fungus Dinemasporium 
strigosum and showed anti-microbial activity (Figure 2). 20-23 
 
  
Figure 2.  Biologically active simple spiroketals. 
These results clearly demonstrate that simple spiroketals inspired to natural bioactive products 
can be privileged scaffolds for new lead compounds endowed with interesting biological activity.  
Recently, some of us have synthesized a new structurally simplified spiroketal 12 that has shown 
potent antitumor activity against tumor cells of various nature and histotype (Figure 3).24  
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The simple spiroketalic structure of this compound is equipped with different stereocentres and 
its synthesis afforded a stereoisomeric mixture of the spiroketal 12 that as such was initially 
submitted to biological assay. Intrigued by the potent antitumor activity of the stereoisomeric 
mixture we decided to investigate the activity of the enantiomerically pure spiroketals. Here we 
describe the synthesis and the characterization of the stereoisomeric mixture of the spiroketal 12, 
their stereoisomeric separation and the biological evaluation of the stereoisomeric mixture and the 
enantiomerically pure spiroketals. On the basis of docking and circular dichroism (CD) studies we 
highlighted that spiroketals induced telomerase inhibition could be determined by a spiroketal 
interaction with the telomerase enzyme rather than by a G-quadruplex (G4) stabilization 
mechanism.  
 
RESULTS AND DISCUSSION 
Chemistry. 
The synthesis of the spiroketal derivative 12 has been performed via an oxidation-rearrangement 
of 2-furyl ketone 15 readily available by reaction of furyllithium with -hexalactone 14 as shown 
in Scheme 1.25,26 Starting from the racemic -hexalactone 14, only two spiroketal diastereomers in 
3:1 isomers ratio were detected via NMR, each consisting of a racemic mixture. The stereoisomers 
detected in the reaction mixture were supposed to have the configurations shown in Scheme 1 for 
compounds 12a,b [(2S,6S,8R) and (2R,6R,8S)] and 12c,d [(2R,6S,8R) and (2S,6R,8S)] because 
they are the only stereoisomers favoured from two anomeric effects derived from the axial-axial 
arrangement of the spiro C-O bonds.25,26,27 The configuration of the major diasteromers 12a,b was 
supported by the observation of a Nuclear Overhauser Enhancement between the C-2 hydrogen 
and the C-8 hydrogen. As previously reported on similar spiroketals, the minor diastereomers 
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12c,d were assigned as the thermodynamically less stable corresponding C-2 epimers of 12a,b. 
On the basis of the positive results of the biological tests performed on the mixture of stereoisomers 
12a-d (see below) the separation of the single stereoisomers was then performed by using chiral 
HPLC in order to test their individual biological activity. Finally in order to confirm the absolute 
configuration of the recovered stereoisomers, we carried out the synthesis of the spiroketal mixture 
of 12a and 12c starting from the enantiopure (R)--hexalactone 14 (Scheme 1).  
 
 
Scheme 1. Synthesis of spiroketal stereoisomers starting from racemic and enantiopure (R)--
hexalactone 14 
Chiral HPLC of the stereoisomers mixture of 12a-d 
With the aim to have at disposal milligram amounts of pure enantiomers for biological tests, the 
enantioseparability of the mixture containing the stereoisomers 12a-d was investigated on two 
polysaccharide-based chiral columns (Chiralcel OD-H and Chiralpak IA) by using hex/IPA 95:5 
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as mobile phase (MP) at FR 0.8 ml/min. Four separated peaks were observed on both columns 
(Table 1). In general, the best column/MP chromatographic system can be selected as a suitable 
compromise between a high enough enantioselectivity value, a baseline resolution (Rs ≥ 1.5) and 
a run-time as short as possible to complete the analysis. On this basis, Chiralcel OD-H was chosen 
for the multimilligram recovery of the stereoisomers. Indeed, despite baseline resolution was only 
achieved on Chiralpak IA (Figure 4), shorter elution times were obtained on Chiralcel OD-H , 
allowing to recover the enantiomers 12a and 12b within 15 min.  
 
 
Figure 4. HPLC separation on Chiralpak IA 
Each peak recovered by using Chiralcel OD-H was characterized by NMR spectroscopy. The 
NMR spectra of compounds eluted at 9.16 and 9.58 min (Table 1) allowed the identification of 
compound 16 probably derived by on-column rearrangement of 12, whereas it was possible to 
assign the signals of compounds eluted at 11.24 and 12.23 min to the couple 12a (2S,6S,8R) and 









Chiralcel OD-H Chiralpak IA 






9.58 1.66 9.31 1.44 




12b 12.23 2.40 22.01 4.81 
 
However, 12 showed low on-column stability and this fact limited the recovery yield. Indeed, 
the injection of 28.0 mg of isomeric mixture on Chiralcel OD-H produced 3.9 mg of 12a and 3.3 
mg of 12b (>99% e.e., 26% yield), whereas 45.6 mg of isomeric mixture produced 5.6 mg of each 
enantiomer, namely 12a and 12b (>99% e.e., 25% yield) on Chiralpak IA. To increase throughput, 
the technique of boxcar injections was used for all recoveries. The minor diastereoisomeric couple 
12c,d was not detected by HPLC analysis probably because of the low on column stability of the 
spiroketal 12. The enantiomer elution order was determined by injection of a sample of 





Figure 5. NMR structural characterization of compounds recovered by means of chiral HPLC on 
Chiralcel OD-H. 
Biology.  
Anti-proliferative activity of spiroketals stereoisomeric mixture 12a-d 
First, biological studies on the stereoisomeric mixture of 12a-d have been carried out using 
representative human tumor cell lines with different histological origin: MCF-7 breast carcinoma, 
M14 melanoma, H125 pulmonary carcinoma, HT-29 colon carcinoma, HL-60 promyelocytic 
leukemia and SH-SY5Y neuroblastoma.  The tumor cell growth has been evaluated by counting 
viable cells number by a trypan blue dye exclusion test.  The results, illustrated in Figure 6 in terms 
of viable cell number, showed that spiroketal stereoisomeric mixture 12a-d used at different 
concentrations (7.8 nM, 15,6 nM 31.2 nM, 62.5 nM , 125 nM  250 nM), for culture times from 24 
to 72 hours, induce a remarkable inhibition of cell proliferation. The cell growth inhibition was 
observed in all treated tumor cells and is time and dose correlated. In particular, the treatment with 
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250nM of stereoisomeric mixture (12a-d) induced a potent cytotoxic effect in all lines, since, more 
















































































Figure 6. The antiproliferative effect of the stereoisomeric mixture of 12a-d on human tumor cell 
lines: M14 melanoma, H125 pulmonary carcinoma, HL-60 promyelocytic leukemia, HT-29 colon 
carcinoma, MCF-7 breast carcinoma,  and SH-SY5Y neuroblastoma cell line. Cell growth kinetics 
was evaluated in terms of number of viable cells. The cell proliferation, viability and death have 
been determined by means of cell counts in trypan blue (dye exclusion test). Data are expressed in 
terms of number of viable cells. Measurements were done in triplicate, bars represent ± SE of the 
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mean of three wells. Values are referred to a representative experiment, from least three 
independent experiments. 
Anti-proliferative activity of enantiomerically pure enantiomers 12a and 12b 
The evaluation of anti-proliferative effects has been also carried out using the enantiomerically 
pure enantiomers 12a (2S,6S,8R) and 12b (2R,6R,8S) obtained via chiral HPLC separation. The 
tumor cell line M14 (human melanoma) has been used as representative tumor cell line to compare 
the anti-proliferative effectiveness of 12a and 12b with respect to the stereoisomeric mixture 12a-
d. Treatment was performed with serial concentrations of 12a, 12b and the racemic mixture of 
stereoisomers 12a-d as reference compound from 62.5 nM to 250 nM (12.5, 25, 50, g/mL) at 
culture times varying from 24 to 72 hours. The effect of 12a, 12b and 12a-d on cell proliferation 
of melanoma cell line M14 was determined by cell counts in trypan blue (dye exclusion test) using 
a hemocytometer (see below). Cell proliferation results show that treatment with enantiopure 12a, 
12b and 12a-d stereoisomeric mixture at different concentrations always induce in M14 cell line 
a remarkable inhibition of cell proliferation, depending on culture time and concentration (Figure 
7). In addition, as showed in Figure 8, taking a reference dose 250 nM, the tumor growth inhibition 
is comparable for both enantiomers and the stereoisomeric mixture in M14 line by using a CellTiter 
96®Non-RadioactiveCell Proliferation. The results are referred to optical density (OD). Taking 
together the results showed, a comparable effect of enantiomers 12a and 12b and the 
stereoisomeric mixture 12a-d in inhibiting M14 cell growth. The inhibition activity of both 
enantiomers and the stereoisomeric mixture on M14 cell grow is also substantially comparable 
when evaluated in terms of kinetic cell growth. 
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Figure 7. Effect of pure enantiomers 12a and 12b and stereoisomeric mixture 12a-d on tumor cell 
growth of M14 melanoma cell line.  Cells were cultured in complete medium containing the 
indicated concentrations of 12a, 12b and 12a-d, for 6, 24, 48 and 72 h. Control groups were treated 
with DMSO alone. Cell proliferation was determined by trypan blue dye exclusion assay. Data are 
expressed in terms of viable cells number. Measurements were done in triplicate. Values of a 
representative experiment, from at least three independent experiments, represent the mean ± SE 
of three wells.  
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Figure 8.   Effect of 250nM of pure enantiomers 12a and 12b and stereoisomeric mixture 12a-d 
on tumor cell growth of M14 melanoma cell line evaluated at  24, 48 and 72 h. Cell proliferation 
was determined by CellTiter 96®Non-RadioactiveCell Proliferation. Measurements of optical 
density (OD) were done in triplicate in three different experiments. Data are expressed in terms of 
percentage of cell growth inhibition with respect to control.  
Proapoptotic in vitro activity  
The role of apoptosis in the origin of the inhibitory effect of 12a-d on cell proliferation has been 
previous investigated by flow cytometry.24 In order to confirm this proapoptotic effect of 12a-d, 
the activation of caspases 3/7, which are mediators of apoptosis, was analyzed upon exposure of 
SHSY5Y neuroblastoma cell line to the 12a-d mixture. In order to avoid an excessive cytotoxicity 
the experiments was performed using very low doses (7.8 nM, 15,6 nM, 31.2 nM) of the 12a-d 
mixture and for a relative short time, 24 h.  The levels of caspase activation in SHSY5Y 
neuroblastoma cells were compared with untreated control cells arbitrarily set to 1.0. The results, 
expressed as caspase 3/7 activity fold increase showed that the 12a-d significantly increase caspase 
12a-d 12-a 12-b
24h 36.8 36.7 40.4
48h 56.1 58.1 64.4




























cell growth inhibition with 250 nM concentrations   
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3/7 activation at different concentrations. At 31,2 nM, the caspase 3/7 activity reached a maximum, 
8.2 fold increase at 24h (Figure 9).  
 
Figure 9. Apoptosis mediated by caspase3/7 activation. Treatment of cells with various 
concentration of 12a-d for 24 h. The levels of caspase activation in SHSY5Y neuroblastoma cell 
line were compared with untreated control cells arbitrarily set to 1.0. Measurements were done in 
triplicate, bars represent ± SE of the mean of three wells. Values are referred to a representative 
experiment, from at least three independent experiments. 
Telomerase in vitro activity  
In order to provide additional information on the antitumor effects of 12a-d on malignant cells, 
experiments were performed to test the in vitro influence of the compound on Telomerasic activity 
(TELMA), the enzyme strongly associated with cancer progression and cell immortalization.28-32 
MCF-7, H-125 HT-29 and M14 tumor cells were exposed in vitro to 31,2 nM to 250 nM of 
stereoisomeric mixture 12a-d.  After 48 hours of treatment TELMA was evaluated.  In all 
examined cell lines a reduction of TELMA was observed as shown in Table 2. The results were 
expressed as percentage of inhibition with respect to untreated cell line. The inhibition is 
































most sensible tumor line respect to TELMA inhibition reaching around the 62% of TELMA 
inhibition at the lower concentration of 12a-d (31.2 nM). IC50 of 12a-d ranging from 12,6 to 85,2 
nM depending from the cell lines. To the best of our knowledge the spiroketal 12a-d is one of the 
most potent telomerase inhibitor known. 
 
Table 2. Dose-dependent percent of inhibition of TELMA, respect to untreated control obtained  
by stereoisomeric mixture 12a-d.   
Percent of inhibition of TELMA by 12a-d after 48 h 








MCF7  breast cancer cell 0 37.5 67.9 78.6 
M14   melanoma  62 63 74 82.6 
H125  lung carcinoma  13.6 48.7 67.6 75.7 
HT29  colon carcinoma  24 53.5 69 73.4 
TELMA was detected by telomeric repeat amplification protocol enzyme-linked immunosorbent 
assay after 48 h. The percent of inhibition was calculated between the means of treated versus 
untreated control, all experiments were done in triplicate. 
 
Circular Dichroism Studies  
Since a spiroketal telomerase inhibition effect could be a consequence from a stabilization of 
G4, CD spectroscopy was used to investigate the binding property of the spiroketal stereoisomeric 
mixture to telomeric G4.33-34 In order to investigate the influence of 12a-d towards the G4 stability 
by a sequence taken from the human telomeric DNA, a 2.5 µM solution of tel22 G4 has been 
incubated with 50 eq of 12a-d in two buffer systems: 0.01 M Tris-HCl (pH 7.5), 0.2 M KCl and 
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PBS 1x (pH 7.5). The conformation adopted by tel22 G4, after annealing under the above described 
experimental conditions, is essentially identical to that observed by Hudson et al.35, as confirmed 
by comparison of its CD spectrum with literature reports. Its stability has been analysed by CD-
melting experiments, monitoring the CD signal changes at 295 nm registered upon increasing the 
temperature in the range 10 - 90 °C (Figure 10). G4 exhibits a Tm of 69 °C in 0.01 M Tris-HCl (pH 
7.5), 0.2 M KCl. In contrast, the G4 was markedly less stable in PBS 1x (pH 7.5) exhibiting a Tm 
of 60 °C. After incubation with 12a-d, CD-melting experiments (Figure 10) have been performed 
on the systems G4/12 in both the buffer systems, mixed in 1:50 ratio; these results show that 12a-
d does not affect the CD-melting curve of the G4. 
 
Figure 10. overlapped CD-melting curves of tel22 (2.5 μM, PBS 1x, pH 7.5) in the absence (green 
line) and presence of 50 eq of 12a-d (blue) and tel22 (2.5 μM, 0.01 M Tris-HCl - 0.2 M KCl, pH 
7.5) in the absence (cyan line) and presence of 50 eq of 12a-d (red), recorded at 295 nm with a 
temperature increase of 1 °C/min; 
Molecular Modeling 
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No crystallographic data of human telomerase is available, however a homology model was 
elaborated based on the Tribolium castaneum structure in the past. 36 Skordalakes and co-workers 
highlighted further structural conservative elements between human and Tribolium castaneum 
telomerase. A conserved and solvent-exposed hydrophobic pocket to accomodate small molecules 
is formed by the thumb domains of 20, 21, 22, and 23 helices present in both species 
telomerases.37 We were docking the different spiroketal stereoisomers into the presumed binding 
site formed by the four -helices. We used glide score to rank the poses of 12a-d and glide emodel 
to fetch the best/worst ones. The ligand and the receptor site show nice shape and electrostatic 
complementarity. Our docking studies predicted several van der Waals interactions between the 
aliphatic moiety of the spiroketal scaffold and the hydrophobic residues Phe 482, Ile 556, Ile 550, 
Leu 554 and Phe 494 and hydrogen bonds between the hydroxyl, ether and carbonyl oxygens and 
Leu 554, Asp 493, Asn 492, Arg 486 and Tyr 551. Next we used scorpion analysis ranks ligand 
atoms individually in the context of cooperativity between a protein ligand complex to help 
understanding the network interactions (Figure 11).38 
 
Figure 11. Modeling of spiroketal 12a into the Tribolium castaneum topoisomerase (PDB ID 
5CQG). Left: overview of the -helical secondary structure around the binding pocket. Right: 
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close-up view of the binding site with the spirooxindole 12a shown as cyan sticks and the receptor 
residues as green sticks. Van der Waals, hydrogen bonding and dipolar interactions are shown in 
yellow, red and cyan dotted lines, respectively.  The binding distances are indicated in yellow. The 
picture was rendered with PyMol. 
Scorpion analysis predicted 12a and b as the strongest binder. An exemplary scorpion analysis 
of the highest scoring pose of 12a is shown in Figure 11. The hydroxyl group makes a bifurcated 
hydrogen bonding with the amide carbonyls of Gly495 and Phe494. Plenty of hydrophobic 
contacts are formed between the double bond and the Arg557 and Leu554. The methyl group is 
burried deeply in the receptor pocket and shows a close contact to the m-carbon of Tyr551. The 
spiroketone carbonyl oxygen forms a dipolar interaction with the amide group of Gly553. 
 
CONCLUSIONS 
New structurally simplified spiroketal inspired to natural bioactive products have been 
synthesised. Their enantiomeric separation and characterization has been performed. The 
compounds have shown a high apoptosis induction and one of the most potent human telomerase 
inhibition activity known with also a very high anticancer activity. Cell proliferation results 
showed that the synthesised compounds always induce a remarkable inhibition of cell growth in 
all cell lines treated with spiroketals, depending on culture time and concentration. The inhibition 
activity of both enantiomers on cell grow is substantially comparable. These results confirm the 
previously proposed central role of spiroketals framework for telomerase inhibition activity. 
Furthermore, our CD melting experiments converge in showing that compound 12a-d does not 
affect the G4 thermal stability as revealed on tel22 human telomeric DNA. Our findings suggest 
that the ability of compound 12a-d to interfere with the telomerase activity is not due to any 
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stabilization of telomeric G4 structures but follows other mechanisms. Docking studies showed 
several interactions between the spiroketal scaffold in the active site of telomerase and predict 





1. General Chemistry. All reactions were carried out under a nitrogen atmosphere. Solvents 
were distilled and dried by standard methods. NMR spectra were recorded at room temperature, 
unless stated otherwise, using a 400 MHz, Varian Mercury spectrometer. Shifts have been 
recorded in ppm relative to CDCl3 solvent residual peak. The following abbreviations have been 
used to explain the observed multiplicities: s, singlet; d, doublet; dd, doublet of doublets; ddd, 
doublet of doublets of doublets; t, triplet; td, triplet of doublets; m, multiplet; bs, broad singlet. All 
chemical reagents and solvents were purchased from commercial sources and used without further 
purification. Column chromatography was performed using 230−400 mesh silica gel. Thin-layer 
chromatography (TLC) was used to monitor progress of the reaction. The purity of the final 
compound 12a-d was determined by C, H, N analysis and was in agreement with the proposed 
structures with purity ≥95%. The purity of final compounds 12a and 12b was determined by high 
performance liquid chromatography (HPLC) analysis, with the purity of compounds being higher 
than 95% and >99% of enantiomeric excess. HPLC instrument was a Agilent 1100 Series HPLC 
system [high-pressure binary gradient system equipped with a diode-array detector operating at 
multiple wavelengths (220, 254, 280, 360 nm), a 20 l sample loop and a thermostatted column 
compartment] using Chiralcel® OD-H  or Chiralpak® IA operating as described in the chiral HPLC 
experimental section 2.   
2-(Furan-2-yl)-6-methyltetrahydro-2H-pyran-2-ol (15): Butyllithium (16 mmol) and TMEDA 
(15.1 mmol) were added at 0 °C to a solution of furan 13 (15.1 mmol) in 20 mL of THF and the 
mixture was stirred at the same temperature for three hours. The solution was cooled at  –78 °C 
and then -hexalactone 14 was added. The reaction mixture was stirred at -78 °C for one hour and 
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then quenched by adding 10 mL of a saturated aqueous solution of NH4Cl. The mixture was 
extracted with Et2O (3x20 mL) and CH2Cl2 (3x20 mL) and the organic layers were dried over 
Na2SO4 and filtered. The solvent was then evaporated at room temperature and the crude product 
was purified by flash chromatography (AcOEt/hexanes 2:1) to give compound 15 as a colorless 
oil in a 70% yield. 1H NMR (400 MHz, CDCl3)  7.57 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 3.6 Hz, 
1H), 6,52 (dd, J = 3.6, 1.6 Hz, 1H), 6.36 (bs, 1H, OH), 3.85-3.77 (m, 1H), 2.86 (t, J = 7.2 Hz, 2H), 
1.87-1.75 (m, 2H), 1.54-1.48 (m, 2H), 1.20 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3)  
189.6, 152.5, 146.2, 117.0, 112.1, 67.3, 38.5, 38.0, 23.3, 20.1. Anal. Calcd for C10H14O3: C 65.91, 
H 7.74. Found: C 65.01, H 7.20.        
2-Hydroxy-8-methyl-1,7-dioxaspiro[5.5]undec-3-en-5-one (12a-d): NBS (0.2 mmol) was added 
to a solution of 15 (0.1 mmol) in 5 mL of THF/H2O (4:1) at 0 °C. The mixture was stirred for 1.5 
h at 0 °C, quenched with 5 mL of an aqueous solution of Na2S2O3, neutralized by adding an 
aqueous solution of NaHCO3 and extracted with CH2Cl2 (3x20 mL). The organic phase was 
separated, dried over Na2SO4 filtered, and the solvent was evaporated under reduced pressure. The 
crude product was purified by flash chromatography (AcOEt/ hexanes 2:1) to give 12a-d as a 
colorless oil in a 95% yield. 1H NMR (400 MHz, CDCl3)  6.95 (dd, J = 14.0, 3.6 Hz, 1Ha), 6.90 
(dd, J = 10.2, 1.2 Hz, 1Hb), 6.12 (dd, J = 10.2, 1.6 Hz, 1Hb), 6.11 (dd, J = 10.4, 0.8 Hz, 1Ha), 5.67 
(d, J = 9.2 Hz, 1Hb), 5.46 (dd, J = 11.6, 2.8 Hz, 1Ha), 4.38-4.30 (m, 1Ha), 4.04-3.96 (m, 1Hb), 
2.18-2.06 (m, 1Ha, 1Hb), 1.96-1.84 (m, 1Ha, 1Hb), 1.77-1.48 (m, 3Ha, 3Hb), 1.39-1.31 (m, 1Ha, 
1Hb), 1.16 (d, J = 6.0 Hz, 3Hb), 1.13 (d, J = 6.4 Hz, 3Ha). 13C NMR (100 MHz, CDCl3) 190.2, 
178.2, 148.1, 145.2, 126.5, 124.7, 88.0, 87.3, 70.3, 69.1, 35.0, 34.0, 31.9, 27.7, 27.0, 21.4, 19.8, 
17.9. Anal. Calcd for C10H14O4: C 60.59, H 7.12. Found: C 60.90, H 7.27.   
2. Chiral HPLC  
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Instrument. An Agilent Technologies (Waldbronn, Germany) 1100 Series HPLC system [high-
pressure binary gradient system equipped with a diode-array detector operating at multiple 
wavelengths (220, 254, 280, 360 nm), a 20 l sample loop and a thermostatted column 
compartment] was employed both for analytical enantioseparations and multimilligram recovery 
of the enantiomers. Data acquisition and analysis were carried out with Agilent Technologies 
ChemStation Version B.04.03 chromatographic data software. The UV absorbance is reported as 
milliabsorbance units (mAU). 
Chromatography. Chiralcel® OD-H (cellulose tris-3,5-dimethylphenylcarbamate) (Daicel, 
Japan) and Chiralpak® IA (amylose tris-3,5-dimethylphenylcarbamate) (Chiral Technologies 
Europe, Ilkirch, France) were used as analytical chiral columns (250 x 4.6 mm, 5 m). HPLC-
grade n-hexane (hex) and 2-propanol (IPA) were purchased from Sigma-Aldrich (Taufkirchen, 
Germany). Analyses were performed in isocratic mode. The retention factor (k) was determined 
as k = (tR-t0)/t0, where tR is the retention time for the eluted enantiomer: k1 is the retention factor of 
the first-eluted enantiomer. The separation factor () was calculated as  = k2/k1. The resolution 
(Rs) was determined as 2(tR2-tR1)/(W1+W2) where W is the basewidth of peak. Dead time (t0 = 3.6 
min (OD-H), 3.8 min (IA)) was measured by injection of tri-tert-butylbenzene (Sigma-Aldrich, 
Germany) as a non-retained compound at flow rate (FR) = 0.8 ml/min.39 For analytical runs, 
sample solutions were prepared by dissolving analytes in hex/IPA 1:1 (1.0-2.0 mg/ml). For 
multimilligram enantioseparations, the feed concentration of sample was 30 mg/ml (hex/IPA 1:1). 
Chromatographic separations were performed at 22°C.  
3. Cell Proliferation Inhibition Assay 
Cell lines 
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The study has been carried out using human tumor cell lines with different histological origin: 
MCF-7 breast carcinoma, M14 melanoma, H125 pulmonary carcinoma, HT-29 colon carcinoma, 
HL-60 promyelocytic leukemia. SH-SY5Y subline of the neuroblastoma cell line SK-N-SH.  
MCF7, H125, HT29 SH-SY5Y and HL60 were obtained from American Type Culture Collection 
(Rockville, MD).  M14 (Golub et al., 1992), was kindly provided by Dr. G. Zupi (Istituto Regina 
Elena Rome, Italy).  All cell lines were cultured at 37°C in 5% CO2 humidified atmosphere and 
maintained in RPMI-1640 or DMEM F12 (Hyclone Europe, Cramlington, UK) supplemented with 
10% heat-inactivated (56°C, 30 min) fetal calf serum (Hyclone Laboratories, Logan, UT), 2 mM 
L-glutamine, and antibiotics (Life Technologies Ltd., Paisley, Scotland) (referred to as complete 
medium, CM). Adherent cells were released from flasks by brief exposure to 0.025% trypsin with 
0.01%EDTA. 
Antiproliferative activity  
Cell growth and viability was determined by trypan blue dye exclusion test. Cells were seeded 
in 24-well tissue culture plates (Falcon) at a concentration of 5x104 cells/mL and allowed to adhere 
overnight. Cells were incubated with 12a-d (7.8 to 250 nM) or DMSO alone as control,  3 wells 
for each treatment. The plates were incubated at 37˚C in a 5% CO2 humidified atmosphere for 24, 
48 or 72 h. Cell growth and viability were evaluated every 24 h. Trypsinized cells were manually 
counted using a hemocytometer and cell viability was determined by trypan blue dye exclusion 
assay. 
The effect of 12a-d or enantiomers 12a and 12b on cell proliferation of melanoma cell line M14 
was determined by the CellTiter 96®Non-RadioactiveCell Proliferation (Promega Madison, WI, 
USA). Briefly, the cell suspension at an initial density of 8×104 cells/mL was seeded into 96-well 
plates and allowed to adhere overnight. Then, cells were treated with DMSO alone as control and 
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12a-d, 12a and 12b (62.5, 125, 250 nM) for 6, 12, 24, 48 and 72 h. After treatment, the dye solution 
was added to the cell culture. Following incubation 4 h, the solubilization/stop solution was added 
to each well. The absorbance at wavelength of 570 nm was measured by an enzyme-linked 
immunoabsorbent assay reader. The negative control well contained medium only and was used 
as zeropoint of absorbance. The relative inhibition rate was calculated as a percentage, as follows: 
(A control- A experiment/A control-A negtive control)×100%. 
4. Caspase-Glo® 3/7 assay 
To confirm apoptosis induction, Caspase-3/7 activities were measured using Caspase-Glo® 3/7 
assay kit (Promega, Madison, WI, USA) according to manufacturer’s instructions40 Briefly, tumor 
cells SHSY5Ywere seeded in 96-well tissue culture plates (Falcon) at a concentration of 5x104 
cells/ml and allowed to adhere overnight. After that the cells were exposed to of 12a-d (7.8 to 31.2 
nM) for 24 hours. The cells were incubated for 1 hour at 37°C with equal volume of Caspase-
Glo® 3/7 reagent to the volume of culture medium. Adding the Caspase-Glo® 3/7 Reagent in an 
"add-mix-measure" format results in cell lysis, followed by caspase cleavage of the substrate. This 
liberates free aminoluciferin, which is consumed by the luciferase, generating a "glow-type" 
luminescent signal. The luminescence that is proportional to caspase 3/7 activities was determined 
by luminometer. A negative control consisting of cells treated with DMSO. supernatant containing 
12a-d alone  was also included in each assay. The test was performed in triplicate. 
5. Telomerase in vitro activity  
In order to evaluate telomerase activity, MCF-7, H-125, M14 and H125 tumor cells were treated 
for 48 hours with serial doses of 12a-d (from 31.2 to 250 nM) as described above. At the end of 
the treatment, the cells were harvested and washed twice with washing buffer and lysed in the lysis 
buffer. Supernatants were collected, rapidly frozen and stored at -80˚C until the use. The 
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telomerase activity was determined using the TeloTAGGG telomerase PCR-ELISA plus Detection 
Kit according to the manufacturer's protocol (Roche Applied Science, Germany). Briefly, the cell 
extracts were incubated in presence of biotin-labeled primers for 30 min and the telomeric repeats 
were built by cell-extracted telomerase. Subsequently, the elongated products as well as especial 
internal standard were amplified by PCR and then, the PCR products were denatured and split in 
two aliquots and each separately hybridized to a digoxigenin-labeled detection specific probes and 
was then allowed to bind to a streptavidin coated 96-well plate and the biotin-labeled PCR products 
were detected using peroxidase-conjugated antibody. Finally, the absorbance of developed blue 
color was measured at 450 nm by an ELISA reader.  The telomerase activity was measured in 
triplicate. As the negative control, each extract was heated at 95°C for 10 min prior to the PCR 
step. Relative telomerase activity (RTA) of each sample was calculated according to the instruction 
of TeloTAGGG Telomerase PCR-ELISA PLUS kit. 
6. Circular Dichroism studies  
Preparation of the ODN model system 
The human telomeric sequence 5′-d(AGGGTTAGGGTTAGGGTTAGGG)-3′ (Tel-22), was 
obtained from Eurofins Genomics (Ebersberg, Germany). DNA samples were prepared by 
dissolving the deoxyoligonucleotide in 0.01 M Tris-HCl (pH 7.5), 0.2 M KCl and PBS 1x (pH 
7.5), followed by an annealing process in which the DNA solution was heated to 95 °C and slowly 
cooled to 4 °C over 12 hours. The formation of the G4 was confirmed at a concentration of 2.5 μM 
(strand) in a 1 cm path length cell using an Jasco J-810 spectropolarimeter: CD spectra in TRIS-
K+ buffer  showed a positive CD band centred at about 295 nm, which is characteristic of 
antiparallel G4 DNA structure, while in PBS 1X Tel-22 gave a CD spectrum compatible with that 
previously reported in the literature (Hudson et al. 2014).  
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CD-monitored melting experiments 
For the CD melting experiments, the ellipticity has been recorded at 295 nm with a temperature 
scan rate of 1 °C/min in the range 10-90 °C. Tm values of 60 °C and 69 °C have been determined, 
respectively, for the G4 model systems in our two buffer conditions (0.01 M Tris-HCl (pH 7.5), 
0.2 M KCl and PBS 1x (pH 7.5). All the CD melting experimentshave been performed in triplicate 
in a 1 cm path length cell at 2.5 μM concentration of G4. 
7. Docking studies 
3D structures of 12a and 12b were generated using LigPrep, version 3.8 (Schrödinger, LLC, 
New York, NY, 2016) and Tribolium castaneum catalytic subunit of telomeras tcTERT in complex 
with highly specific BIBR1532 inhibitor (PDB ID: 5CQG) was prepared with protein preparation 
wizard. Grid receptor generation and docking studies were performed using Glide, while the 
receptor was keept rigid (version 7.1, Schrödinger, LLC, New York, NY, 2016). 
 
Statistical analysis 
Results means ± SE. Statistical significance was determined using Student's t test. 
 
Abbreviations Used   
TELMA, Telomerasic activity; OD optical density; G4, G-quadruplex; CD, circular dichroism; 
IPA, 2-propanol; ODN, oligonucleotide. 
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